BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sensus Healthcare Announces Sale of 100th Skin Cancer Treatment Device


9/26/2012 9:46:30 AM

BOCA RATON, Fla., Sept. 26, 2012 /PRNewswire/ -- SensusHealthcare is proud to announce a major milestone in selling its 100th SRT-100 advanced superficial radiotherapy (SRT) system. The SRT-100 is a global success for treating Non Melanoma Skin Cancer on all major continents. The SRT-100 provides patients with a virtually pain-free non-invasive treatment option, while achieving excellent outcomes that are comparable to surgery, and without scarring. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) to the global clinical community as a viable, safe, and cost-effective modality to treat non-melanoma skin cancers in hospitals and private practice settings.

"We are delighted and very proud to have reached this important milestone so soon with the SRT-100. The rapid growth and broad clinical acceptance of the SRT-100 in radiation oncology and dermatology is a strong testimony to the viability and efficacy of our state-of-the-art solution in treating non-melanoma skin cancers. It is imperative to our mission to provide the physicians and their patients with more treatment options while improving their quality of life as they battle their skin cancer. We are grateful to all our customers who put their trust in us and are looking forward to serve them for many years to come. We are looking forward to reaching many new milestones and achievements, together with our customers, on the path of improving the lives and outcomes of all non-melanoma skin cancer patients!" stated Joe Sardano, President/CEO, Sensus Healthcare.

SRT-100 is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.

About Sensus Healthcare:

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100 systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings.

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. 100
michelle@sensushealthcare.com

SOURCE Sensus Healthcare



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES